The Acquisition of NexGenAI Affiliates Network
Expands Company's Capabilities and Drives Innovation, Operational
Efficiency, and Opportunity for Growth
WEXFORD, Pa. , Dec. 3, 2024
/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)
(the "Company" or "Coeptis"), a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases, is pleased to announce the
execution of a Binding Letter of Intent for the acquisition of
NexGenAI Affiliates Network, a platform developed by NexGenAI
Solutions Group and its affiliates ("NexGenAI") that offers
AI-powered marketing software and robotic process automation
("RPA") capabilities. By integrating AI-powered solutions and RPA
tools, Coeptis not only enhances its operational efficiency but
also positions itself to leverage these advanced technologies for
broader applications, creating new opportunities for growth while
maintaining its primary focus on biopharmaceutical innovation.
NexGenAI has developed a suite of innovative marketing tools
that utilize AI and RPA to optimize campaigns, streamline
workflows, and generate actionable insights. By acquiring these
assets, Coeptis will bring these state-of-the-art solutions to
companies seeking to overcome marketing challenges in competitive
and highly regulated sectors, particularly in the biotech,
pharmaceutical and multi-level marketing ("MLM") industries. These
tools will help companies run smarter, more efficient marketing
campaigns, saving time and resources while staying compliant with
strict regulations.
Dave Mehalick, President and CEO
of Coeptis Therapeutics commented, "We are excited to integrate
NexGenAI Affiliates Network and groundbreaking AI and RPA-driven
tools into our offerings. In industries like biotech, pharma, and
MLM, where competition is so high and regulatory challenges are
complex, having advanced tools to optimize marketing, streamline
operations, and drive measurable results is critical."
Anshuman Dash, Lead Advisory
behind the development of NexGenAI Affiliates Network commented,
"The integration of NexGenAI's innovative AI-powered marketing
solutions with Coeptis Therapeutics' forward-thinking approach
marks a transformative step forward. This acquisition not only
validates the cutting-edge technology we've developed but also
aligns with Coeptis' mission to drive innovation in highly
regulated industries. Together, we aim to revolutionize marketing
strategies and operational efficiencies, ultimately delivering
greater value to our partners and the industries we serve."
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
About NexGenAI:
NexGenAI Holding Group Inc., along
with its majority-owned subsidiary NexGenAI Solutions Group, Inc.,
has developed a proprietary suite of advanced tools that power the
NexGenAI Affiliates Network platform. These tools, featuring
AI-driven marketing software and robotic process automation
capabilities, are designed to optimize campaigns, streamline
operations, and provide actionable, data-driven insights.
NexGenAI's platform provides cutting-edge AI-driven solutions that
revolutionize business operations across various sectors. By
leveraging artificial intelligence, NexGenAI empowers companies to
automate processes, optimize efficiency, and drive sustainable
growth. For more information on NexgenAI go to nexgenai.io.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the risk that the integration of the Deverra licensed assets
will disrupt current plans and operations of the Company; (3) the
inability to recognize the anticipated benefits of the
newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-executes-binding-letter-of-intent-to-acquire-ai-powered-marketing-solutions-for-biotech-pharmaceutical-and-other-industries-302320336.html
SOURCE Coeptis Pharmaceuticals, Inc.